This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Atogepant in the prevention of migraine

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There has been the discovery that migraine attacks may be related to the provocation action of calcitonin gene-related peptide (CGRP) (1).

Atogepant is a CGRP receptor antagonist (gepant) that is used in the prevention of migraine:

  • is an orally administered small molecule that has a much shorter half-life than CGRP monoclonal antibodies and may have the advantage of being more convenient and acceptable for some specific patients
  • in terms of dosing frequency, the small molecule atogepant needs to be taken orally every day
  • with regard to treatment-related adverse events, gastrointestinal symptoms such as nausea and constipation are the most common (1)
  • has shown good efficacy and safety in the prophylactic treatment of migraine
  • daily use of oral atogepant 60 mg for the preventive treatment of migraine during a 1‐year, open‐label trial was safe and well tolerated (2)

NICE state (3):

  • Atogepant is recommended as an option for preventing migraine in adults who have at least 4 migraine days per month, only if at least 3 preventive medicines have failed
  • Stop atogepant after 12 weeks if the frequency of migraines does not reduce by
    • at least 50% in episodic migraine (defined as fewer than 15 headache days per month)
    • at least 30% in chronic migraine (defined as 15 or more headache days per month, with at least 8 of those having features of migraine).


  1. Tao X, Yan Z, Meng J, Wang W, Dai Q, Zhou Q, Wang Z, Wang Z. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain. 2022 Jan 29;23(1):19.
  2. Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J, Miceli R, Severt L, Finnegan M, Trugman JM. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023 Jan;63(1):79-88.
  3. NICE (May 2024). Atogepant for preventing migraine

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.